European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)

You might also be interested in reading Tom Lee urges BitMine shareholders to approve share increase ahead of January 14 vote.